全文获取类型
收费全文 | 95479篇 |
免费 | 7296篇 |
国内免费 | 216篇 |
专业分类
耳鼻咽喉 | 770篇 |
儿科学 | 3721篇 |
妇产科学 | 3012篇 |
基础医学 | 12576篇 |
口腔科学 | 1546篇 |
临床医学 | 14985篇 |
内科学 | 17833篇 |
皮肤病学 | 1638篇 |
神经病学 | 9193篇 |
特种医学 | 1935篇 |
外国民族医学 | 33篇 |
外科学 | 8436篇 |
综合类 | 1006篇 |
一般理论 | 140篇 |
预防医学 | 12545篇 |
眼科学 | 1223篇 |
药学 | 5373篇 |
3篇 | |
中国医学 | 138篇 |
肿瘤学 | 6885篇 |
出版年
2023年 | 665篇 |
2022年 | 821篇 |
2021年 | 2201篇 |
2020年 | 1567篇 |
2019年 | 2416篇 |
2018年 | 2700篇 |
2017年 | 2020篇 |
2016年 | 2259篇 |
2015年 | 2399篇 |
2014年 | 3167篇 |
2013年 | 4956篇 |
2012年 | 6970篇 |
2011年 | 7322篇 |
2010年 | 3951篇 |
2009年 | 3607篇 |
2008年 | 6196篇 |
2007年 | 6713篇 |
2006年 | 6535篇 |
2005年 | 6241篇 |
2004年 | 6066篇 |
2003年 | 5666篇 |
2002年 | 5217篇 |
2001年 | 735篇 |
2000年 | 524篇 |
1999年 | 697篇 |
1998年 | 1146篇 |
1997年 | 896篇 |
1996年 | 773篇 |
1995年 | 687篇 |
1994年 | 626篇 |
1993年 | 618篇 |
1992年 | 437篇 |
1991年 | 384篇 |
1990年 | 366篇 |
1989年 | 290篇 |
1988年 | 300篇 |
1987年 | 276篇 |
1986年 | 248篇 |
1985年 | 279篇 |
1984年 | 305篇 |
1983年 | 306篇 |
1982年 | 386篇 |
1981年 | 368篇 |
1980年 | 289篇 |
1979年 | 198篇 |
1978年 | 183篇 |
1977年 | 178篇 |
1976年 | 156篇 |
1975年 | 127篇 |
1973年 | 124篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
71.
72.
Curtis Hose Gurmeet Kaur Edward A Sausville Anne Monks 《Clinical cancer research》2005,11(17):6370-6381
73.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
74.
75.
Marie-Paule Roth Hlne Coppin Patrick Descoins Jean-Bernard Ruidavets Anne Cambon-Thomsen Michel Clanet 《Journal of neuroimmunology》1991,34(2-3):215-222
The polymorphism at the HLA-DPB1 locus has been characterized in a large number of patients with multiple sclerosis (n = 112) and in healthy controls (n = 115). Both patients and controls lived in the southwest of France (in the Pyrénées Atlantiques) and had similar ethnic background. The typing procedure involved the selective amplification of the second exon of the DPB1 locus by polymerase chain reaction, followed by hybridization of the amplified DNA with 14 sequence-specific oligonucleotide probes. Individual alleles were identified by the pattern of hybridization of the different probes. The distribution of the DPB1 alleles was not significantly different in multiple sclerosis patients and controls (p = 0.11). This does not corroborate the reported association of multiple sclerosis with the primed lymphocyte typing (PLT)-defined DPw4 specificity and is not in favour of a role played by polymorphic residues of the DP molecule in susceptibility to multiple sclerosis. 相似文献
76.
77.
78.
79.
Hong Li Fassil Ketema Anne M Sill Kristen M Kreisel Farley R Cleghorn Niel T Constantine 《International journal of infectious diseases》2007,11(5):459-465
OBJECTIVES: We sought to modify the Serodia HIV-1/HIV-2 particle agglutination assay (PA), a simple and cost-effective HIV assay that is used globally for the detection of HIV antibodies, as a sensitive/less sensitive test (S/LS) to identify recently infected individuals and to estimate HIV incidence. METHODS: The Serodia PA test was modified as an S/LS test (PA-LS) by using HIV antigen-coated gelatin particles at a dilution of 1:68 and a specific diluent, and calibrated using 37 HIV clade B seroconversion panels (309 samples) from Trinidad and from a commercial source that were tested at dilution intervals from 1:10 to 1:80,000. The greatest sensitivity for correctly classifying samples from recent and established infections was determined by receiver operator curve (ROC) analysis. RESULTS: At a 1:40,000 sample dilution and a days post-seroconversion cutoff of 190 days, the PA-LS test yielded a 97% sensitivity for classifying recent and established infection samples. Furthermore, at a 1:20,000 dilution, the positive predictive value for correctly identifying recently infected individuals was 99%. The PA-LS test offers a 30-44-fold cost saving over currently available S/LS tests. CONCLUSION: A modified, low cost and simple-to-perform PA test is appropriate for use in resource-limited countries, and has exhibited excellence in distinguishing recent from established HIV infection. 相似文献
80.
Bradley J Catalone Shendra R Miller Mary Lee Ferguson Dan Malamud Tina Kish-Catalone Nina J Thakkar Fred C Krebs Mary K Howett Brian Wigdahl 《Biomedicine & Pharmacotherapy》2005,59(8):430-437
C31G, which has potent activity against the human immunodeficiency virus type 1 (HIV-1) and an established record of safety in animal studies and human trials, is a microbicidal agent comprised of a buffered equimolar mixture of two amphoteric, surface-active agents: an alkyl amine oxide (C14AO) and an alkyl betaine (C16B). Studies of long-term in vitro exposure to C31G and its constituents have suggested that the components of C31G may contribute differentially to its toxicity and efficacy. In the present studies, in vitro assays of cytotoxicity and anti-HIV-1 activity demonstrated that C16B was slightly less cytotoxic compared to either C31G or C14AO, whereas the anti-HIV-1 activities of C31G and its individual constituents were similar. In the murine model of cervicovaginal microbicide toxicity, in vivo exposure to C14AO resulted in severe cervical inflammation followed by a delayed disruption of the columnar epithelium. In contrast, exposure to C16B caused severe cervical epithelial disruption and a secondary, less intense inflammatory response. These results demonstrate that (i) there are both mechanistic and temporal differences in toxicity associated with the components of C31G not necessarily predicted by in vitro assessments of cytotoxicity and (ii) contributions of each component to the anti-HIV-1 activity of C31G appear to be equal. In addition, these findings indicate that direct and indirect mechanisms of in vivo toxicity can be observed as separate but interrelated events. These results provide further insight into the activity of C31G, as well as mechanisms potentially associated with microbicide toxicity. 相似文献